NeurAxis Achieves a Major Milestone in Abdominal Pain Treatment
NeurAxis, Inc. is excited to announce a significant advancement in the treatment of Functional Abdominal Pain (FAP) associated with Irritable Bowel Syndrome (IBS). Recently, clinical practice guidelines released in a reputable journal recognized Percutaneous Electrical Nerve Field Stimulation (PENFS) as a recommended treatment for this condition, significantly marking NeurAxis's contributions to pediatric care.
PENFS Technology: A Game Changer for Pediatric Patients
Among the highlighted treatment options in the guidelines, NeurAxis's PENFS stands out as the only FDA-cleared treatment indicated for pediatric patients. This recognition not only solidifies the technology's credibility but also opens doors for extensive insurance coverage. NeurAxis’s flagship product, IB-Stim, utilizes this innovative technology to enhance patient outcomes, fostering hope for many families dealing with chronic abdominal pain.
CEO's Vision for Growth
Brian Carrico, the CEO of NeurAxis, expressed his enthusiasm regarding this newfound recognition. He articulated, "We are thrilled that IB-Stim is now recognized as part of the standard of care for FAP in IBS. This milestone offers new hope to our patients and strengthens our growth strategy." This achievement is not just a victory for NeurAxis but for the countless children who suffer from these debilitating symptoms every day.
Evidence-Based Recommendations Boost Market Potential
The recent guidelines, formulated through a collaborative effort from leading pediatric gastroenterology affiliations, followed the rigorous “Grading of Recommendations Assessment, Development and Evaluation” (GRADE) methodology. PENFS was included due to its compelling evidence supporting its safety and efficacy, enhancing NeurAxis's profile within an increasingly competitive market.
Understanding Functional Abdominal Pain and Its Impact
Millions of children are affected by abdominal pain related to IBS, presenting a significant healthcare challenge. The market potential is vast, with over 600,000 American children experiencing FAP, contributing to an estimated market value exceeding three billion dollars. However, many are left to navigate their treatment options with limited effective solutions, emphasizing the need for innovative therapies like IB-Stim.
Non-invasive and Safe Treatment Alternatives
IB-Stim offers a non-invasive alternative to traditional drug therapies, which are often used off-label and present various risks. This innovative device works by delivering gentle electrical impulses to specific nerve bundles in the ear, aligning with modern healthcare's focus on minimizing invasive procedures and side effects.
Collaborative Guidelines Enhance Decision-Making
Dr. Adrian Miranda, Chief Medical Officer at NeurAxis, highlighted the collaborative development of these guidelines, which aim to establish a framework for shared decision-making between clinicians and families. This approach allows more flexibility in treatment options and reinforces the importance of IB-Stim in clinical settings, positioning it favorably among other therapies.
Future Opportunities for NeurAxis
The acknowledgment of IB-Stim in these guidelines paves the way for NeurAxis to drive substantial growth. With ongoing FDA clearances and a new Category I CPT code expected to launch shortly, the company is poised for significant operational leverage and increased top-line growth.
Building on Strong Foundations
Strengthened by a recent boost to its financial standing, NeurAxis is equipped to broaden its reach. By expanding insurance coverage for IB-Stim, they aim to provide a critical solution for pediatric patients suffering from FAP, fundamentally changing the landscape of treatment options available.
Frequently Asked Questions
What is IB-Stim?
IB-Stim is a medical device developed by NeurAxis that utilizes Percutaneous Electrical Nerve Field Stimulation (PENFS) to treat Functional Abdominal Pain in children with Irritable Bowel Syndrome (IBS).
How does PENFS work?
PENFS delivers gentle electrical impulses to cranial nerve bundles in the ear, providing a non-invasive treatment option for managing abdominal pain.
What recent developments have influenced NeurAxis's success?
Key developments include the recognition of IB-Stim in clinical guidelines and expanded FDA clearances, enabling more widespread insurance coverage for patients.
Why is the inclusion of IB-Stim in the guidelines important?
This inclusion reinforces IB-Stim as a credible treatment option and enhances its accessibility for the pediatric population suffering from chronic abdominal pain.
What is the market potential for IB-Stim?
With over 600,000 children in the US experiencing Functional Abdominal Pain, the estimated market potential for IB-Stim is over three billion dollars, highlighting the significant demand for effective treatment solutions.
